Lyell Immunopharma

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.

Business Model:

Revenue: $39.1M

Employees: 51-200

Rankings

Detailed Lyell Immunopharma Information

Geographic Data

Lyell Immunopharma headquarters map

Address: 201 Haskins Way

City: South San Francisco

State: CA

Zip: 94080

Country: US

Financial Info

Stage:

Raised Last:

$493M

Raised Total:

$493M

Metrics

4,381,179Website Global Rank

2,283Website Monthly Traffic

Twitter Followers

Description

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.

Contact Phone:
+16506950677

Contact Email:

Lyell Immunopharma went public on 6/16/2021 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
6/16/2021

IPO Valuation:
$4B

Ticker Symbol:
LYEL

IPO Price:
$17/share

Amount Raised:
$425M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
3/2020 Cero Therapeutics Series A 0
2/2020 Sonoma BioTherapeutics Series A 0
9/2020 Sonoma Pharmaceuticals Post-IPO Equity 70M
3/2021 Outpace Bio Series A 30M
9/2020 Sonoma BioTherapeutics Series A 0
3/2020 Eureka Therapeutics Series E 0
3/2021 Outpace Bio Series A 0
9/2020 Sonoma BioTherapeutics Series A 0
9/2020 Sonoma Pharmaceuticals Post-IPO Equity 0
3/2020 Cero Therapeutics Series A 0
3/2020 Eureka Therapeutics Series E 0
2/2020 Sonoma BioTherapeutics Series A 0
Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research